Heron Therapeutics, Inc. announced on May 6, 2025, that it has entered into a settlement agreement with Mylan Pharmaceuticals, Inc. to resolve ongoing patent litigations. The litigations in the U.S. District Court for the District of Delaware pertained to CINVANTI (aprepitant) injectable emulsion and APONVIE (aprepitant) injectable emulsion.
Under the terms of the settlement, Heron has granted Mylan a license under the Orange Book-listed patents for CINVANTI and APONVIE. This license permits Mylan to market generic versions of these products in the United States starting June 1, 2032, or earlier under specific customary circumstances.
This agreement provides long-term clarity regarding the market exclusivity of CINVANTI and APONVIE, as Heron's patents for these products expire in 2035. The settlement resolves the patent litigations initiated by Heron in September 2023 and January 2024, which were in response to Mylan's abbreviated new drug applications seeking generic approvals prior to patent expiration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.